The present application relates to a drug delivery ocular implant (53) comprising an outer shell (54) having a proximal end (52), a distal end (50), said outer shell being shaped to define an interior space (58) at least a first therapeutic agent (62) positioned within said interior space (58), and a crimp cap (53a, 54a) sealed to the proximal end (52) of said outer shell (54). According to the invention, said crimp cap (53a, 54a) comprises at least one aperture, a membrane (60, 60a) permeable to said at least a first therapeutic agent positioned between said crimp cap (53a, 54a) and said proximal end (52) of said outer shell (54), wherein said membrane (60, 60a) occludes said at least one aperture, thereby allowing elution of said at least a first therapeutic agent (62) to occur only through said membrane (60, 60a), and a retention protrusion (359) on the distal end (50) of said outer shell (54), wherein said retention protrusion (359) is configured to anchor the ocular implant (53) at a target tissue site in the eye. At least one fluid inflow pathway (38k) and one fluid outflow pathway (56k) are positioned adjacent the distal end (50) of said outer shell (54), and said at least one fluid outflow pathway (56k) allows ocular fluid to be directed through the implant via at least one fluid inflow pathway (38k) to deliver ocular fluid from an anterior chamber (20) to a physiological outflow space (22).L'invention porte sur des dispositifs et sur des procédés d'administration de médicament pour le traitement de troubles oculaires nécessitant une administration ciblée et contrôlée d'un médicament dans une partie intérieure de l'œil pour la réduction ou la prévention de symptômes du trouble. Lesdits dispositifs permettent une libération contrôlée d'un ou plusieurs médicaments et peuvent également comprendre des structures qui permettent le traitement de la pression intraoculaire accrue par le fait de permettre à l'humeur aqueuse de s'écouler hors de la chambre intérieur
